{"protocolSection":{"identificationModule":{"nctId":"NCT03358875","orgStudyIdInfo":{"id":"BGB-A317-303"},"secondaryIdInfos":[{"id":"2018-000245-39","type":"EUDRACT_NUMBER"},{"id":"CTR20171112","type":"REGISTRY","domain":"ChinaDrugTrials"}],"organization":{"fullName":"BeiGene","class":"INDUSTRY"},"briefTitle":"Comparison of Efficacy and Safety of Tislelizumab (BGB-A317) Versus Docetaxel as Treatment in the Second- or Third-line Setting in Participants With Non-Small Cell Lung Cancer (NSCLC)","officialTitle":"A Phase 3, Open-Label, Multicenter, Randomized Study to Investigate the Efficacy and Safety of BGB-A317 (Anti-PD1 Antibody) Compared With Docetaxel in Patients With Non-Small Cell Lung Cancer Who Have Progressed on a Prior Platinum-Containing Regimen","acronym":"RATIONALE-303"},"statusModule":{"statusVerifiedDate":"2025-01","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2017-11-30","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2021-07-15","type":"ACTUAL"},"completionDateStruct":{"date":"2024-01-18","type":"ACTUAL"},"studyFirstSubmitDate":"2017-11-27","studyFirstSubmitQcDate":"2017-11-27","studyFirstPostDateStruct":{"date":"2017-12-02","type":"ACTUAL"},"resultsFirstSubmitDate":"2025-01-16","resultsFirstSubmitQcDate":"2025-01-16","resultsFirstPostDateStruct":{"date":"2025-02-10","type":"ACTUAL"},"lastUpdateSubmitDate":"2025-01-16","lastUpdatePostDateStruct":{"date":"2025-02-10","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"BeiGene","class":"INDUSTRY"}},"oversightModule":{"oversightHasDmc":true,"isFdaRegulatedDrug":false,"isFdaRegulatedDevice":false},"descriptionModule":{"briefSummary":"The purpose of this study is to show that tislelizumab will improve overall survival in participants with Stage IIIB or IV non-small cell lung cancer when compared to docetaxel in second or third-line treatment setting.","detailedDescription":"This is a randomized, open-label, multicenter Phase 3 study in adult participants with histologically confirmed, locally advanced or metastatic (Stage IIIB or IV), NSCLC (squamous or non-squamous) who have disease progression during or after a platinum-containing regimen."},"conditionsModule":{"conditions":["Non-small Cell Lung Cancer"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE3"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"NONE"}},"enrollmentInfo":{"count":805,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"Tislelizumab","type":"EXPERIMENTAL","description":"Participants received tislelizumab 200 mg intravenously (IV) once every 3 weeks until disease progression, unacceptable toxicity, or withdrawal of informed consent, whichever occurred first.","interventionNames":["Drug: Tislelizumab"]},{"label":"Docetaxel","type":"ACTIVE_COMPARATOR","description":"Participants received docetaxel 75 mg/m² IV once every 3 weeks until disease progression, unacceptable toxicity, or withdrawal of informed consent, whichever occurred first.","interventionNames":["Drug: Docetaxel"]}],"interventions":[{"type":"DRUG","name":"Tislelizumab","description":"Tislelizumab administered by intravenous (IV) infusion","armGroupLabels":["Tislelizumab"],"otherNames":["BGB-A317","TEVIMBRA®"]},{"type":"DRUG","name":"Docetaxel","description":"Docetaxel administered as an IV infusion over 1 hour","armGroupLabels":["Docetaxel"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Overall Survival (OS) in All Participants (Co-primary Endpoint)","description":"OS was defined as the time from randomization to death from any cause. Median OS was calculated using the Kaplan-Meier method. Data for participants who were not reported as having died at the time of analysis were censored at the date they were last known to be alive. Data for participants who did not have postbaseline information were censored at the date of randomization.","timeFrame":"From randomization to the data cutoff date of 10 August 2020; up to 32.4 months"},{"measure":"Overall Survival (OS) in Programmed Cell Death Protein Ligand-1 (PD-L1)-Positive Participants (Co-primary Endpoint)","description":"OS was defined as the time from randomization to death from any cause. Median OS was calculated using the Kaplan-Meier method. Data for participants who were not reported as having died at the time of analysis were censored at the date they were last known to be alive. Data for participants who did not have postbaseline information were censored at the date of randomization.","timeFrame":"From randomization up to the final efficacy analysis data cut-off date of 15 July 2021; Up to 43 months"}],"secondaryOutcomes":[{"measure":"Objective Response Rate (ORR) in All Participants","description":"Objective response rate is defined as the percentage of participants who had a complete response (CR) or partial response (PR) as assessed by the investigator per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 Tumor assessments included computed tomography (CT) scans or magnetic resonance imaging (MRI), with preference for CT, of the chest, abdomen, and pelvis.\n\nCR: Disappearance of all target and non-target lesions and no new lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \\< 10 mm.\n\nPR: At least a 30% decrease in the size of target lesions and no progression of non-target lesions and no new lesions, or disappearance of all target lesions with persistence of one or more non-target lesion(s) and/or maintenance of tumor marker level above the normal limits and no new lesions.","timeFrame":"From randomization up to the final efficacy analysis data cut-off date of 15 July 2021; Up to 43 months"},{"measure":"Objective Response Rate in PD-L1-Positive Participants","description":"Objective response rate is defined as the percentage of participants who had a complete response (CR) or partial response (PR) as assessed by the investigator per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 Tumor assessments included computed tomography (CT) scans or magnetic resonance imaging (MRI), with preference for CT, of the chest, abdomen, and pelvis.\n\nCR: Disappearance of all target and non-target lesions and no new lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \\< 10 mm.\n\nPR: At least a 30% decrease in the size of target lesions and no progression of non-target lesions and no new lesions, or disappearance of all target lesions with persistence of one or more non-target lesion(s) and/or maintenance of tumor marker level above the normal limits and no new lesions.","timeFrame":"From randomization up to the final efficacy analysis data cut-off date of 15 July 2021; Up to 43 months"},{"measure":"Duration of Response (DOR) for All Responders","description":"DoR was defined as the time from the first documented objective response to documented disease progression as assessed by the investigator using RECIST v1.1, or death from any cause, whichever occurred first.\n\nMedian DOR was estimated using the Kaplan-Meier method.\n\nProgressive Disease (PD): At least a 20% increase in the size of target lesions with an absolute increase of at least 5 mm, or unequivocal progression of existing non-target lesions, or the appearance of any new lesions.","timeFrame":"From randomization up to the final efficacy analysis data cut-off date of 15 July 2021; Up to 43 months"},{"measure":"Duration of Response (DOR) in PD-L1-Positive Responders","description":"DoR was defined as the time from the first documented objective response to documented disease progression as assessed by the investigator using RECIST v1.1, or death from any cause, whichever occurred first.\n\nMedian DOR was estimated using the Kaplan-Meier method.\n\nProgressive Disease (PD): At least a 20% increase in the size of target lesions with an absolute increase of at least 5 mm, or unequivocal progression of existing non-target lesions, or the appearance of any new lesions.","timeFrame":"From randomization up to the final efficacy analysis data cut-off date of 15 July 2021; Up to 43 months"},{"measure":"Progression-free Survival (PFS) in All Participants","description":"PFS was defined as the time from randomization to the first objectively documented disease progression as assessed by the investigator per RECIST v1.1 or death from any cause, whichever occurred first.\n\nMedian PFS was estimated using the Kaplan-Meier method.","timeFrame":"From randomization up to the final efficacy analysis data cut-off date of 15 July 2021; Up to 43 months"},{"measure":"Progression-free Survival in PD-L1 Positive Participants","description":"PFS was defined as the time from randomization to the first objectively documented disease progression as assessed by the investigator per RECIST v1.1 or death from any cause, whichever occurred first.\n\nMedian PFS was estimated using the Kaplan-Meier method.","timeFrame":"From randomization up to the final efficacy analysis data cut-off date of 15 July 2021; Up to 43 months"},{"measure":"Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Global Health Status (GHS)/Quality of Life (QOL) Score","description":"The EORTC QLQ-30 contains 30 questions that incorporate 5 functional scales (physical functioning, role functioning, emotional functioning, cognitive functioning, and social functioning), 1 global health status scale, 3 symptom scales (fatigue, nausea and vomiting, and pain), and 6 single items (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties). The participant answers questions about their health during the past week. There are 28 questions answered on a 4-point scale where 1 = Not at all (best) and 4 = Very Much (worst) and two global health quality of life (QOL) questions answered on a 7-point scale where 1 = Very poor and 7 = Excellent. Raw scores are transformed into a 0 to 100 scale via linear transformation. Higher scores in GHS/QoL score indicates better quality of life.","timeFrame":"Baseline and Cycle 6 (each cycle was 3 weeks)"},{"measure":"Change From Baseline in EORTC Quality of Life Questionnaire Lung Cancer 13 Items (QLQ-LC13) Coughing, Dyspnoea, and Chest Pain Scores","description":"The EORTC QLQ-LC13 is the lung cancer module of the QLQ-C30 and measures lung cancer-specific disease and treatment symptoms. It includes 13 questions about specific symptoms in which participants respond based on a 4-point scale, where 1 is \"not at all\" and 4 is \"very much\". Raw scores are transformed into a 0 to 100 scale via linear transformation. Lower scores indicate an improvement in symptoms.","timeFrame":"Baseline and Cycle 6 (each cycle was 3 weeks)"},{"measure":"Change From Baseline in European Quality of Life 5-Dimensions, 5-level (EQ-5D-5L) Visual Analogue Scale (VAS)","description":"The EQ-5D-5L measures health outcomes using a VAS to record a participant's self-rated health on a scale from 0 to 100, where 100 is 'the best health you can imagine' and 0 is 'the worst health you can imagine.' A higher score indicates better health outcomes.","timeFrame":"Baseline and Cycle 6 (each cycle was 3 weeks)"},{"measure":"Number of Participants With Treatment-emergent Adverse Events (TEAEs)","description":"An adverse event is defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study drug, whether considered related to study drug or not.\n\nThe investigator assessed the severity of each AE and graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) v4.03 as defined below:\n\n* Grade 1: Mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated.\n* Grade 2: Moderate; minimal, local or noninvasive intervention indicated; limiting age-appropriate activities of daily living.\n* Grade 3: Severe or medically significant but not immediately life threatening. hospitalization or prolongation of hospitalization indicated; disabling; limiting selfcare activities of daily living.\n* Grade 4: Life threatening consequences; urgent intervention indicated.\n* Grade 5: Death related to AE.","timeFrame":"From first dose of study drug to 30 days after last dose, up to the study completion date cut-off date of 18 January 2024 (up to approximately 63 months)"}]},"eligibilityModule":{"eligibilityCriteria":"Key Inclusion Criteria:\n\n1. Age ≥ 18 years.\n2. Signed Informed Consent Form.\n3. Histologically confirmed locally advanced or metastatic (Stage IIIB or IV) NSCLC of either squamous or non-squamous histology types with disease progression during or following treatment with at least one platinum-containing regimen, but no more than 2 lines of systemic therapy.\n4. Participants must be able to provide fresh or archival tumor tissues for central assessment of PD-L1 expression in tumor cells. Participants with non-squamous histology must provide evidence of not harboring sensitizing epidermal growth factor (EGFR) mutation tested by a histology-based method.\n5. Eastern Cooperative Oncology Group (ECOG) performance status ≤ 1.\n6. Adequate hematologic and end-organ function.\n7. Expected life span \\> 12 weeks.\n8. Willing to be compliance with birth control requirement during pre-specified study participating period\n\nKey Exclusion Criteria:\n\n1. Prior therapies of docetaxel or treatment targeting programmed cell death protein 1 (PD-1), PD-L1 or cytotoxic T-lymphocyte associated protein 4 (CTLA-4).\n2. Harboring EGFR sensitizing mutation or anaplastic lymphoma kinase (ALK) gene translocation.\n3. Unresolved side effects of Grade 2 and above from prior anti-cancer therapies, except for adverse events (AEs) not constituting a likely safety risk (e.g. alopecia, rash, pigmentation, specific lab abnormalities).\n4. History of severe hypersensitivity reactions to other monoclonal antibodies (mAbs).\n5. History of interstitial lung disease, non-infectious pneumonitis or participants with significantly impaired pulmonary function, or who require supplemental oxygen at baseline.\n6. With uncontrollable pleural effusion, pericardial effusion, or clinically significant ascites requiring interventional treatment.\n7. Active leptomeningeal disease or uncontrolled, untreated brain metastasis.\n8. Severe chronic or active infection requiring systemic treatment.\n9. Known human immunodeficiency virus (HIV) infection, participants with untreated chronic hepatitis B, active vaccination treatment.\n10. Insufficient cardiac functions and other underlying unfavorable cardiovascular conditions.\n11. Prior allogeneic stem cell transplantation or organ transplantation.\n12. Active autoimmune diseases or history of autoimmune diseases that may relapse.\n13. With conditions requiring systemic treatment with either corticosteroids (\\>10 mg daily prednisone or equivalent) or other immunosuppressive medications.\n14. With severe underlying medical conditions (including laboratory abnormalities) or alcohol or drug abuse that may affect the explanation of drug toxicity or AEs or result in impaired compliance with study conduct.\n\nNOTE: Other protocol defined Inclusion/Exclusion criteria may apply.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Caicun Zhou, PhD","affiliation":"Shanghai Pulmonary Hospital, Shanghai, China","role":"PRINCIPAL_INVESTIGATOR"}],"locations":[{"facility":"Hospital de Amor Barretos","city":"Barretos","zip":"14784-400","country":"Brazil","geoPoint":{"lat":-20.55722,"lon":-48.56778}},{"facility":"Hospital Evangelico de Cachoeiro de Itapemirim","city":"Cachoeiro de Itapemirim","zip":"29308-020","country":"Brazil","geoPoint":{"lat":-20.84889,"lon":-41.11278}},{"facility":"Hospital Haroldo Juacaba Instituto Do Cancer Do Ceara","city":"Fortaleza","zip":"60430-230","country":"Brazil","geoPoint":{"lat":-3.71722,"lon":-38.54306}},{"facility":"Oncosite Centro de Pesquisa Clinica Em Oncologia","city":"Ijuí","zip":"98700-000","country":"Brazil","geoPoint":{"lat":-28.38778,"lon":-53.91472}},{"facility":"Fundacao Doutor Amaral Carvalho","city":"Jaú","zip":"17210-120","country":"Brazil","geoPoint":{"lat":-22.29639,"lon":-48.55778}},{"facility":"Hospital Bruno Born","city":"Lajeado","zip":"95900-000","country":"Brazil","geoPoint":{"lat":-23.53361,"lon":-46.40866}},{"facility":"Hospital Sao Vicente de Paulo","city":"Passo Fundo","zip":"99010-080","country":"Brazil","geoPoint":{"lat":-28.26278,"lon":-52.40667}},{"facility":"Hgb Hospital Giovanni Battista Mae de Deus Center","city":"Porto Alegre","zip":"90470-340","country":"Brazil","geoPoint":{"lat":-30.03283,"lon":-51.23019}},{"facility":"Hospital Sao Lucas Da Pucrs","city":"Porto Alegre","zip":"90610-000","country":"Brazil","geoPoint":{"lat":-30.03283,"lon":-51.23019}},{"facility":"Hospital Nossa Senhora Da Conceicao","city":"Porto Alegre","zip":"91350-200","country":"Brazil","geoPoint":{"lat":-30.03283,"lon":-51.23019}},{"facility":"Hospital de Clinicas de Porto Alegre","city":"Porto AlegreRS","zip":"900350-903","country":"Brazil"},{"facility":"Inca Instituto Nacional de Cancer","city":"Rio de Janeiro","zip":"20231-050","country":"Brazil","geoPoint":{"lat":-22.90642,"lon":-43.18223}},{"facility":"Nob Nucleo de Oncologia Da Bahia","city":"Salvador","zip":"40170-110","country":"Brazil","geoPoint":{"lat":-12.97563,"lon":-38.49096}},{"facility":"Cepho Centro de Estudos E Pesquisas de Hematologia E Oncologia","city":"Santo André","zip":"09060-650","country":"Brazil","geoPoint":{"lat":-23.66389,"lon":-46.53833}},{"facility":"Fundacao Faculdade Regional de Medicina de Sao Jose Do Rio Preto","city":"São José do Rio Preto","zip":"15090-000","country":"Brazil","geoPoint":{"lat":-20.81972,"lon":-49.37944}},{"facility":"Icesp Instituto Do Cancer Do Estado de Sao Paulo Octavio Frias de Oliveira","city":"São Paulo","zip":"01246-000","country":"Brazil","geoPoint":{"lat":-23.5475,"lon":-46.63611}},{"facility":"Umhat Deva Maria, Eood","city":"Burgas","zip":"8000","country":"Bulgaria","geoPoint":{"lat":42.50651,"lon":27.46886}},{"facility":"Mhat Dobrich, Ad","city":"Dobrich","zip":"9300","country":"Bulgaria","geoPoint":{"lat":43.56491,"lon":27.83138}},{"facility":"Mhat Dr Tota Venkova, Ad","city":"Gabrovo","zip":"5300","country":"Bulgaria","geoPoint":{"lat":42.87419,"lon":25.31823}},{"facility":"Complex Oncology Center Rousse Eood","city":"Rousse","zip":"7000","country":"Bulgaria","geoPoint":{"lat":43.84872,"lon":25.9534}},{"facility":"Mhat For Womens Health Nadezhda, Ood","city":"Sofia","zip":"1330","country":"Bulgaria","geoPoint":{"lat":42.69751,"lon":23.32415}},{"facility":"Acibadem City Clinic Mhat Tokuda Ead","city":"Sofia","zip":"1407","country":"Bulgaria","geoPoint":{"lat":42.69751,"lon":23.32415}},{"facility":"Anhui Provincial Hospital","city":"Hefei","state":"Anhui","zip":"230000","country":"China","geoPoint":{"lat":31.86389,"lon":117.28083}},{"facility":"The First Affiliated Hospital of Anhui Medical University","city":"Hefei","state":"Anhui","zip":"230000","country":"China","geoPoint":{"lat":31.86389,"lon":117.28083}},{"facility":"Cancer Hospital Chinese Academy of Medical Sciences","city":"Beijing","state":"Beijing Municipality","zip":"100021","country":"China","geoPoint":{"lat":39.9075,"lon":116.39723}},{"facility":"Beijing Cancer Hospital","city":"Beijing","state":"Beijing Municipality","zip":"100142","country":"China","geoPoint":{"lat":39.9075,"lon":116.39723}},{"facility":"Peking Union Medical College Hospital","city":"Beijing","state":"Beijing Municipality","zip":"100730","country":"China","geoPoint":{"lat":39.9075,"lon":116.39723}},{"facility":"Chinese Pla General Hospital","city":"Beijing","state":"Beijing Municipality","zip":"100853","country":"China","geoPoint":{"lat":39.9075,"lon":116.39723}},{"facility":"Beijing Chest Hospital, Capital Medical University","city":"Beijing","state":"Beijing Municipality","zip":"101149","country":"China","geoPoint":{"lat":39.9075,"lon":116.39723}},{"facility":"Daping Hospital, Third Military Medical University","city":"Chongqing","state":"Chongqing Municipality","zip":"400042","country":"China","geoPoint":{"lat":29.56026,"lon":106.55771}},{"facility":"Cancer Center of Guangzhou Medical University","city":"Guangzhou","state":"Guangdong","zip":"510030","country":"China","geoPoint":{"lat":23.11667,"lon":113.25}},{"facility":"Guangzhou Institute of Respiratory Disease","city":"Guangzhou","state":"Guangdong","zip":"510120","country":"China","geoPoint":{"lat":23.11667,"lon":113.25}},{"facility":"Cancer Hospital of Shantou University Medical College","city":"Shantou","state":"Guangdong","zip":"515031","country":"China","geoPoint":{"lat":23.35489,"lon":116.67876}},{"facility":"The First Affiliated Hospital of Guangxi Medical University","city":"Nanning","state":"Guangxi","zip":"530021","country":"China","geoPoint":{"lat":22.81667,"lon":108.31667}},{"facility":"The Affiliated Hospital of Zunyi Medical College","city":"Zunyi","state":"Guizhou","zip":"563000","country":"China","geoPoint":{"lat":27.68667,"lon":106.90722}},{"facility":"Hainan General Hospital","city":"Haikou","state":"Hainan","zip":"570206","country":"China","geoPoint":{"lat":20.03421,"lon":110.34651}},{"facility":"Harbin Medical University Cancer Hospital","city":"Harbin","state":"Heilongjiang","zip":"150000","country":"China","geoPoint":{"lat":45.75,"lon":126.65}},{"facility":"Henan Cancer Hospital","city":"Zhengzhou","state":"Henan","zip":"450000","country":"China","geoPoint":{"lat":34.75778,"lon":113.64861}},{"facility":"Tongji Hospital of Tongji Medical College Huazhong University of Science and Technology","city":"Wuhan","state":"Hubei","zip":"430030","country":"China","geoPoint":{"lat":30.58333,"lon":114.26667}},{"facility":"Hubei Cancer Hospital","city":"Wuhan","state":"Hubei","zip":"430079","country":"China","geoPoint":{"lat":30.58333,"lon":114.26667}},{"facility":"Changsha Central Hospital","city":"Changsha","state":"Hunan","zip":"410004","country":"China","geoPoint":{"lat":28.19874,"lon":112.97087}},{"facility":"Xiangya Hospital of Central South University","city":"Changsha","state":"Hunan","zip":"410008","country":"China","geoPoint":{"lat":28.19874,"lon":112.97087}},{"facility":"Hunan Cancer Hospital","city":"Changsha","state":"Hunan","zip":"410013","country":"China","geoPoint":{"lat":28.19874,"lon":112.97087}},{"facility":"Jiangsu Province Hospital","city":"Nanjing","state":"Jiangsu","zip":"210029","country":"China","geoPoint":{"lat":32.06167,"lon":118.77778}},{"facility":"Nantong Tumor Hospital Branch North","city":"Nantong","state":"Jiangsu","zip":"226000","country":"China","geoPoint":{"lat":32.03028,"lon":120.87472}},{"facility":"The Second Affiliated Hospital of Soochow University","city":"Suzhou","state":"Jiangsu","zip":"215000","country":"China","geoPoint":{"lat":31.30408,"lon":120.59538}},{"facility":"Xuzhou Central Hospital","city":"Xuzhou","state":"Jiangsu","zip":"221000","country":"China","geoPoint":{"lat":34.20442,"lon":117.28386}},{"facility":"Jiangxi Province Cancer Hospital","city":"Nanchang","state":"Jiangxi","zip":"330029","country":"China","geoPoint":{"lat":28.68396,"lon":115.85306}},{"facility":"Jilin Cancer Hospital","city":"Changchun","state":"Jilin","zip":"130021","country":"China","geoPoint":{"lat":43.88,"lon":125.32278}},{"facility":"The First Hospital of Jilin University","city":"Changchun","state":"Jilin","zip":"130021","country":"China","geoPoint":{"lat":43.88,"lon":125.32278}},{"facility":"The First Hospital of China Medical University","city":"Shenyang","state":"Liaoning","zip":"110001","country":"China","geoPoint":{"lat":41.79222,"lon":123.43278}},{"facility":"Liaoning Cancer Hospital and Institute","city":"Shenyang","state":"Liaoning","zip":"110042","country":"China","geoPoint":{"lat":41.79222,"lon":123.43278}},{"facility":"The First Affiliated Hospital of Xian Jiaotong University","city":"Xi'an","state":"Shaanxi","zip":"710061","country":"China","geoPoint":{"lat":34.25833,"lon":108.92861}},{"facility":"Jinan Central Hospital","city":"Jinan","state":"Shandong","zip":"250013","country":"China","geoPoint":{"lat":36.66833,"lon":116.99722}},{"facility":"Linyi Cancer Hospital","city":"Linyi","state":"Shandong","zip":"276001","country":"China","geoPoint":{"lat":35.06306,"lon":118.34278}},{"facility":"Rui Jin Hospital Shanghai Jiao Tong University School of Medicine","city":"Shanghai","state":"Shanghai Municipality","zip":"200025","country":"China","geoPoint":{"lat":31.22222,"lon":121.45806}},{"facility":"Shanghai Pulmonary Hospital","city":"Shanghai","state":"Shanghai Municipality","zip":"200433","country":"China","geoPoint":{"lat":31.22222,"lon":121.45806}},{"facility":"Sichuan Academy of Medical Sciences and Sichuan Provincial Peoples Hospital","city":"Chengdu","state":"Sichuan","zip":"610071","country":"China","geoPoint":{"lat":30.66667,"lon":104.06667}},{"facility":"Tianjin Medical University Cancer Institute and Hospital","city":"Tianjin","state":"Tianjin Municipality","zip":"300060","country":"China","geoPoint":{"lat":39.14222,"lon":117.17667}},{"facility":"Tianjin Union Medical Center (Nankai University Affiliated Hospital)","city":"Tianjin","state":"Tianjin Municipality","zip":"300121","country":"China","geoPoint":{"lat":39.14222,"lon":117.17667}},{"facility":"The First Affiliated Hospital of Xinjiang Medical University","city":"Ürümqi","state":"Xinjiang","zip":"830054","country":"China","geoPoint":{"lat":43.80096,"lon":87.60046}},{"facility":"Yunnan Cancer Hospital","city":"Kunming","state":"Yunnan","zip":"650100","country":"China","geoPoint":{"lat":25.03889,"lon":102.71833}},{"facility":"The First Affiliated Hospital, Zhejiang University School of Medicine","city":"Hangzhou","state":"Zhejiang","zip":"310003","country":"China","geoPoint":{"lat":30.29365,"lon":120.16142}},{"facility":"Zhejiang University College of Medicine Second Affiliated Hospital","city":"Hangzhou","state":"Zhejiang","zip":"310009","country":"China","geoPoint":{"lat":30.29365,"lon":120.16142}},{"facility":"Zhejiang Cancer Hospital","city":"Hangzhou","state":"Zhejiang","zip":"310022","country":"China","geoPoint":{"lat":30.29365,"lon":120.16142}},{"facility":"The First Affiliated Hospital of Wenzhou Medical University","city":"Wenzhou","state":"Zhejiang","zip":"325000","country":"China","geoPoint":{"lat":27.99942,"lon":120.66682}},{"facility":"Hospital of Lithuanian University of Health Sciences Kaunas Clinics Branch Oncology Hospital","city":"Kaunas","zip":"45427","country":"Lithuania","geoPoint":{"lat":54.90156,"lon":23.90909}},{"facility":"Hospital of Lithuanian University of Health Sciences Kaunas Clinics","city":"Kaunas","zip":"50103","country":"Lithuania","geoPoint":{"lat":54.90156,"lon":23.90909}},{"facility":"National Cancer Institute","city":"Vilnius","zip":"8660","country":"Lithuania","geoPoint":{"lat":54.68916,"lon":25.2798}},{"facility":"Investigacion Onco Farmaceutica (Oncotech)","city":"La Paz","zip":"23040","country":"Mexico","geoPoint":{"lat":24.14231,"lon":-110.31316}},{"facility":"Fundacion Rodolfo Padilla Padilla, Ac","city":"León","zip":"37000","country":"Mexico","geoPoint":{"lat":25.60187,"lon":-103.47698}},{"facility":"Health Pharma Professional Research Sa de Cv","city":"Mexico City","zip":"03100","country":"Mexico","geoPoint":{"lat":19.42847,"lon":-99.12766}},{"facility":"Medica Sur","city":"México","zip":"14050","country":"Mexico","geoPoint":{"lat":31.00435,"lon":-108.15213}},{"facility":"Accelerium S de Rl de Cv","city":"Monterrey","zip":"64000","country":"Mexico","geoPoint":{"lat":25.68435,"lon":-100.31721}},{"facility":"Centro de Investigacion Clinica Chapultepec Sa de Cv","city":"Morelia","zip":"58260","country":"Mexico","geoPoint":{"lat":19.70078,"lon":-101.18443}},{"facility":"Oaxaca Site Management Organization Sc","city":"Oaxaca City","zip":"68000","country":"Mexico","geoPoint":{"lat":17.06025,"lon":-96.72544}},{"facility":"Auckland City Hospital","city":"Auckland","zip":"1023","country":"New Zealand","geoPoint":{"lat":-36.84853,"lon":174.76349}},{"facility":"Waikato Hospital","city":"Hamilton Waikato","zip":"3204","country":"New Zealand"},{"facility":"Tauranga Hospital","city":"Tauranga","zip":"3112","country":"New Zealand","geoPoint":{"lat":-37.68611,"lon":176.16667}},{"facility":"Szpital Specjalistyczny Brzeziny","city":"Brzeziny","zip":"95-060","country":"Poland","geoPoint":{"lat":51.80023,"lon":19.75144}},{"facility":"Uniwersyteckie Centrum Kliniczne","city":"Gdansk","zip":"80-952","country":"Poland","geoPoint":{"lat":54.35227,"lon":18.64912}},{"facility":"Centrum Terapii Wspolczesnej Jm Jasnorzewska Sp Komandytowo Akcyjna","city":"Lodz","zip":"90-242","country":"Poland","geoPoint":{"lat":51.77058,"lon":19.47395}},{"facility":"Salve Medica Sp Z Oo, Sp Komandytowa","city":"Lodz","zip":"91-211","country":"Poland","geoPoint":{"lat":51.77058,"lon":19.47395}},{"facility":"Zespol Gruzlicy I Chorob Pluc W Olsztynie Oddz Onkologii Z Pododdz Chemioterapii Nowotworow Puc","city":"Olsztyn","zip":"10-357","country":"Poland","geoPoint":{"lat":53.78376,"lon":20.49272}},{"facility":"Mazowiecki Szpital Specjalistyczny W Ostrolece Im Dr Jozefa Psarskiego","city":"Ostrołęka","zip":"07-410","country":"Poland","geoPoint":{"lat":53.08621,"lon":21.57566}},{"facility":"Mazowieckie Centrum Leczenia Chorob Pluc I Gruzlicy","city":"Otwock","zip":"05-400","country":"Poland","geoPoint":{"lat":52.10577,"lon":21.26129}},{"facility":"Izerskie Centrum Pulmonologii I Chemioterapii Izer Med Spolka Z Oo","city":"Szklarska Porba","zip":"58-580","country":"Poland"},{"facility":"Centrum Onkologii Instytut Im M Sklodowskiej Curie","city":"Warsaw","zip":"02-034","country":"Poland","geoPoint":{"lat":52.22977,"lon":21.01178}},{"facility":"Arkhangelsk Regional Clinical Oncological Dispensary","city":"Arkhangelsk","state":"Arkhangelskaya oblast","zip":"163045","country":"Russia","geoPoint":{"lat":64.5461,"lon":40.55183}},{"facility":"Irkutsk Regional Oncology Dispensary","city":"Irkutsk","state":"Irkutiskaya Oblast'","zip":"664035","country":"Russia","geoPoint":{"lat":52.29566,"lon":104.29076}},{"facility":"Fsbi of Higher Educationogarev Mordovia State University","city":"Saransk","state":"Mordoviya, Respublika","zip":"430005","country":"Russia","geoPoint":{"lat":54.18485,"lon":45.17166}},{"facility":"N N Blokhin Russian Cancer Research Center Konstantin Laktionov","city":"Moscow","state":"Moscow","zip":"115478","country":"Russia","geoPoint":{"lat":55.75204,"lon":37.61781}},{"facility":"Fsbi Russian Scientific Center of Radiology and Nuclear Medicine of the Moh of the Rf","city":"Moscow","state":"Moscow","zip":"117837","country":"Russia","geoPoint":{"lat":55.75204,"lon":37.61781}},{"facility":"Vitamed Llc","city":"Moscow","state":"Moscow","zip":"121309","country":"Russia","geoPoint":{"lat":55.75204,"lon":37.61781}},{"facility":"Bih of Omsk Region Clinical Oncology Dispensary","city":"Omsk","state":"Omsk Oblast","zip":"644013","country":"Russia","geoPoint":{"lat":54.99244,"lon":73.36859}},{"facility":"Sbei Hpe Ryazan State Medical University Na Academician Ip Pavlov of the Moh of the Rf","city":"Ryazan","state":"Ryazan Oblast","zip":"390026","country":"Russia","geoPoint":{"lat":54.62696,"lon":39.70415}},{"facility":"Private Medical Institution Evromedservis","city":"Pushkin","state":"Sankt-Peterburg","zip":"7042","country":"Russia","geoPoint":{"lat":59.71417,"lon":30.39642}},{"facility":"Pavlov First Saint Petersburg State Medical University","city":"SaintPetersburg","state":"Sankt-Peterburg","zip":"197022","country":"Russia"},{"facility":"Llc Center of Palliative Medicine Devita","city":"SaintPetersburg","state":"Sankt-Peterburg","zip":"197183","country":"Russia"},{"facility":"Fsbi Clinical Research and Practical Center For Specialized Medical Care (Oncology)","city":"SanktPetersburg","state":"Sankt-Peterburg","zip":"197758","country":"Russia"},{"facility":"State Budgetary Healthcare Institution Volgograd Regional Clinical Oncology Dispensary","city":"Volgograd","state":"Volgograd Oblast","zip":"400138","country":"Russia","geoPoint":{"lat":48.71378,"lon":44.4976}},{"facility":"Fsbi National Medical Research Center For Oncology Na Nn Petrov of the Moh of the Rf","city":"SaintPetersburg","zip":"197758","country":"Russia"},{"facility":"Fakultna Nemocnica S Poliklinikou Fd Roosevelta","city":"Banská Bystrica","zip":"97409","country":"Slovakia","geoPoint":{"lat":48.73947,"lon":19.14932}},{"facility":"Nemocnica S Poliklinikou Sv Jakuba, No Bardejov","city":"Bardejov","zip":"8501","country":"Slovakia","geoPoint":{"lat":49.29175,"lon":21.27271}},{"facility":"Narodny Onkologicky Ustav","city":"Bratislava","zip":"83310","country":"Slovakia","geoPoint":{"lat":48.14816,"lon":17.10674}},{"facility":"Vychodoslovensky Onkologicky Ustav, As","city":"Košice","zip":"4191","country":"Slovakia","geoPoint":{"lat":48.71441,"lon":21.25802}},{"facility":"Nemocnica S Poliklinikou Stefana Kukuru Michalovce, As","city":"Michalovce","zip":"7101","country":"Slovakia","geoPoint":{"lat":48.75434,"lon":21.9195}},{"facility":"Fakultna Nemocnica S Poliklinikou Nove Zamky","city":"Nové Zámky","zip":"94002","country":"Slovakia","geoPoint":{"lat":47.98544,"lon":18.16195}},{"facility":"Nemocnica Na Okraji Mesta, No","city":"Partizánske","zip":"95814","country":"Slovakia","geoPoint":{"lat":48.62861,"lon":18.38455}},{"facility":"Poko Poprad Sro","city":"Poprad","zip":"5801","country":"Slovakia","geoPoint":{"lat":49.06144,"lon":20.29798}},{"facility":"Acibadem Adana Hospital","city":"Adana","zip":"01130","country":"Turkey (Türkiye)","geoPoint":{"lat":36.98615,"lon":35.32531}},{"facility":"Hacettepe University","city":"Ankara","zip":"6100","country":"Turkey (Türkiye)","geoPoint":{"lat":39.91987,"lon":32.85427}},{"facility":"Nonu Universitesi Tip Fakultesi","city":"Battalgazi","zip":"44280","country":"Turkey (Türkiye)","geoPoint":{"lat":38.42286,"lon":38.3585}},{"facility":"Tr Trakya University Health Research and Application Center (Hospital)","city":"Edirne","zip":"22030","country":"Turkey (Türkiye)","geoPoint":{"lat":41.67719,"lon":26.55597}},{"facility":"Bakirkoy Dr Sadi Konuk Teaching and Research Hospital","city":"Istanbul","zip":"34147","country":"Turkey (Türkiye)","geoPoint":{"lat":41.01384,"lon":28.94966}},{"facility":"Goztepe Prof Dr Suleyman Yalcin Ehir Hastanesi","city":"Istanbul","zip":"34722","country":"Turkey (Türkiye)","geoPoint":{"lat":41.01384,"lon":28.94966}},{"facility":"Ege University Medical Faculty","city":"Izmir","zip":"35100","country":"Turkey (Türkiye)","geoPoint":{"lat":38.41273,"lon":27.13838}},{"facility":"Kocaeli Universitesi Tip Fakultesi","city":"Kocaeli","zip":"41380","country":"Turkey (Türkiye)","geoPoint":{"lat":39.62497,"lon":27.51145}},{"facility":"Necmettin Erbakan University Selcuklu Faculty of Medicine","city":"Meram","zip":"42090","country":"Turkey (Türkiye)","geoPoint":{"lat":37.82985,"lon":32.46777}},{"facility":"Iu C, Clinical Research Excellence Application and Research Center","city":"Stanbul","zip":"34098","country":"Turkey (Türkiye)"},{"facility":"Namik Kemal University","city":"Tekirdağ","zip":"59100","country":"Turkey (Türkiye)","geoPoint":{"lat":40.9781,"lon":27.51101}}]},"referencesModule":{"references":[{"pmid":"36184068","type":"RESULT","citation":"Zhou C, Huang D, Fan Y, Yu X, Liu Y, Shu Y, Ma Z, Wang Z, Cheng Y, Wang J, Hu S, Liu Z, Poddubskaya E, Disel U, Akopov A, Dvorkin M, Zheng W, Ma Y, Wang Y, Li S, Yu C, Rivalland G. Tislelizumab Versus Docetaxel in Patients With Previously Treated Advanced NSCLC (RATIONALE-303): A Phase 3, Open-Label, Randomized Controlled Trial. J Thorac Oncol. 2023 Jan;18(1):93-105. doi: 10.1016/j.jtho.2022.09.217. Epub 2022 Sep 29."},{"pmid":"37587845","type":"RESULT","citation":"Huang D, Zhou C, Barnes G, Ma Y, Li S, Zhan L, Tang B. The effects of tislelizumab treatment on the health-related quality of life of patients with advanced non-small cell lung cancer. Cancer Med. 2023 Aug;12(16):17403-17412. doi: 10.1002/cam4.6361. Epub 2023 Aug 17."}]},"ipdSharingStatementModule":{"ipdSharing":"YES"}},"resultsSection":{"participantFlowModule":{"preAssignmentDetails":"Eligible participants were randomized in a 2:1 ratio to receive either tislelizumab or docetaxel treatment. Randomization was stratified by histology (squamous versus non--squamous), line of therapy (second line versus third line), and programmed cell death protein ligand-1 (PD-L1) expression (≥ 25% tumor cells (TCs) versus \\< 25% TCs).","recruitmentDetails":"This study was conducted at 109 study centers in 10 countries (China, Brazil, Bulgaria, Lithuania, Mexico, New Zealand, Poland, Russia, Slovakia, and Turkey).","groups":[{"id":"FG000","title":"Tislelizumab","description":"Participants received tislelizumab 200 mg intravenously (IV) once every 3 weeks until disease progression, unacceptable toxicity, or withdrawal of informed consent, whichever occurred first."},{"id":"FG001","title":"Docetaxel","description":"Participants received docetaxel 75 mg/m² IV once every 3 weeks until disease progression, unacceptable toxicity, or withdrawal of informed consent, whichever occurred first."}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"535"},{"groupId":"FG001","numSubjects":"270"}]},{"type":"Received Treatment","achievements":[{"groupId":"FG000","numSubjects":"534"},{"groupId":"FG001","numSubjects":"258"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"535"},{"groupId":"FG001","numSubjects":"270"}]}],"dropWithdraws":[{"type":"Death","reasons":[{"groupId":"FG000","numSubjects":"409"},{"groupId":"FG001","numSubjects":"223"}]},{"type":"Study Closed by Sponsor","reasons":[{"groupId":"FG000","numSubjects":"66"},{"groupId":"FG001","numSubjects":"29"}]},{"type":"Withdrawal by Subject","reasons":[{"groupId":"FG000","numSubjects":"13"},{"groupId":"FG001","numSubjects":"16"}]},{"type":"Lost to Follow-up","reasons":[{"groupId":"FG000","numSubjects":"13"},{"groupId":"FG001","numSubjects":"2"}]},{"type":"Miscellaneous","reasons":[{"groupId":"FG000","numSubjects":"33"},{"groupId":"FG001","numSubjects":"0"}]},{"type":"Remained on Study","reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"0"}]}]}]},"baselineCharacteristicsModule":{"groups":[{"id":"BG000","title":"Tislelizumab","description":"Participants received tislelizumab 200 mg IV once every 3 weeks until disease progression, unacceptable toxicity, or withdrawal of informed consent, whichever occurred first."},{"id":"BG001","title":"Docetaxel","description":"Participants received docetaxel 75 mg/m² IV once every 3 weeks until disease progression, unacceptable toxicity, or withdrawal of informed consent, whichever occurred first."},{"id":"BG002","title":"Total","description":"Total of all reporting groups"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"535"},{"groupId":"BG001","value":"270"},{"groupId":"BG002","value":"805"}]}],"measures":[{"title":"Age, Continuous","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"years","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"60.4","spread":"8.79"},{"groupId":"BG001","value":"60.7","spread":"8.95"},{"groupId":"BG002","value":"60.5","spread":"8.84"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"119"},{"groupId":"BG001","value":"64"},{"groupId":"BG002","value":"183"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"416"},{"groupId":"BG001","value":"206"},{"groupId":"BG002","value":"622"}]}]}]},{"title":"Race/Ethnicity, Customized","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"American Indian or Alaska Native","measurements":[{"groupId":"BG000","value":"12"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"13"}]},{"title":"Asian","measurements":[{"groupId":"BG000","value":"424"},{"groupId":"BG001","value":"219"},{"groupId":"BG002","value":"643"}]},{"title":"Black or African American","measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"3"},{"groupId":"BG002","value":"4"}]},{"title":"Native Hawaiian or Other Pacific Islander","measurements":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"3"},{"groupId":"BG002","value":"6"}]},{"title":"White","measurements":[{"groupId":"BG000","value":"93"},{"groupId":"BG001","value":"44"},{"groupId":"BG002","value":"137"}]},{"title":"Other","measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"2"}]}]}]},{"title":"Histology","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Squamous","measurements":[{"groupId":"BG000","value":"248"},{"groupId":"BG001","value":"122"},{"groupId":"BG002","value":"370"}]},{"title":"Non-Squamous","measurements":[{"groupId":"BG000","value":"287"},{"groupId":"BG001","value":"148"},{"groupId":"BG002","value":"435"}]}]}]},{"title":"Current Line of Therapy","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Second line","measurements":[{"groupId":"BG000","value":"453"},{"groupId":"BG001","value":"229"},{"groupId":"BG002","value":"682"}]},{"title":"Third line","measurements":[{"groupId":"BG000","value":"82"},{"groupId":"BG001","value":"41"},{"groupId":"BG002","value":"123"}]}]}]},{"title":"PD-L1 Expression","description":"Participants were tested for PD-L1 expression by a central laboratory using VENTANA SP263 immunohistochemistry assay.","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"≥ 25% of tumor cells","measurements":[{"groupId":"BG000","value":"227"},{"groupId":"BG001","value":"115"},{"groupId":"BG002","value":"342"}]},{"title":"< 25% of tumor cells","measurements":[{"groupId":"BG000","value":"307"},{"groupId":"BG001","value":"152"},{"groupId":"BG002","value":"459"}]},{"title":"Missing","measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"3"},{"groupId":"BG002","value":"4"}]}]}]},{"title":"Smoking Status","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Never","measurements":[{"groupId":"BG000","value":"162"},{"groupId":"BG001","value":"82"},{"groupId":"BG002","value":"244"}]},{"title":"Current","measurements":[{"groupId":"BG000","value":"50"},{"groupId":"BG001","value":"20"},{"groupId":"BG002","value":"70"}]},{"title":"Former","measurements":[{"groupId":"BG000","value":"323"},{"groupId":"BG001","value":"168"},{"groupId":"BG002","value":"491"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Overall Survival (OS) in All Participants (Co-primary Endpoint)","description":"OS was defined as the time from randomization to death from any cause. Median OS was calculated using the Kaplan-Meier method. Data for participants who were not reported as having died at the time of analysis were censored at the date they were last known to be alive. Data for participants who did not have postbaseline information were censored at the date of randomization.","populationDescription":"The Intent-to-Treat (ITT) Analysis Set included all randomized patients","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"months","timeFrame":"From randomization to the data cutoff date of 10 August 2020; up to 32.4 months","groups":[{"id":"OG000","title":"Tislelizumab","description":"Participants received tislelizumab 200 mg IV once every 3 weeks until disease progression, unacceptable toxicity, or withdrawal of informed consent, whichever occurred first."},{"id":"OG001","title":"Docetaxel","description":"Participants received docetaxel 75 mg/m² IV once every 3 weeks until disease progression, unacceptable toxicity, or withdrawal of informed consent, whichever occurred first."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"535"},{"groupId":"OG001","value":"270"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"17.2","lowerLimit":"15.28","upperLimit":"20.04"},{"groupId":"OG001","value":"11.9","lowerLimit":"10.18","upperLimit":"13.93"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"<0.0001","pValueComment":"OS in the ITT population was tested at one-sided p value boundary of 0.0120.","statisticalMethod":"1-sided Log Rank Test","statisticalComment":"Stratified by stratification factors: histology (squamous vs non-squamous), line of therapy (second vs third), and PDL1 expression (≥25% vs \\<25% TC).","paramType":"Hazard Ratio (HR)","paramValue":"0.64","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.527","ciUpperLimit":"0.778","estimateComment":"A stratified Cox proportional hazards model with Efron's method of tie handling was used to determine hazard ratio (HR) and its 95% confidence interval (CI)."}]},{"type":"PRIMARY","title":"Overall Survival (OS) in Programmed Cell Death Protein Ligand-1 (PD-L1)-Positive Participants (Co-primary Endpoint)","description":"OS was defined as the time from randomization to death from any cause. Median OS was calculated using the Kaplan-Meier method. Data for participants who were not reported as having died at the time of analysis were censored at the date they were last known to be alive. Data for participants who did not have postbaseline information were censored at the date of randomization.","populationDescription":"The PD-L1-Positive Analysis Set included all randomized patients whose tumors were PD-L1 positive (defined as ≥ 25% of tumor cells with PD-L1 membrane staining).","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"months","timeFrame":"From randomization up to the final efficacy analysis data cut-off date of 15 July 2021; Up to 43 months","groups":[{"id":"OG000","title":"Tislelizumab","description":"Participants received tislelizumab 200 mg IV once every 3 weeks until disease progression, unacceptable toxicity, or withdrawal of informed consent, whichever occurred first."},{"id":"OG001","title":"Docetaxel","description":"Participants received docetaxel 75 mg/m² IV once every 3 weeks until disease progression, unacceptable toxicity, or withdrawal of informed consent, whichever occurred first."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"227"},{"groupId":"OG001","value":"115"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"19.3","lowerLimit":"16.49","upperLimit":"22.60"},{"groupId":"OG001","value":"11.5","lowerLimit":"8.15","upperLimit":"13.54"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"<0.0001","pValueComment":"OS in the PD-L1 positive analysis set was tested at the one-sided p-value boundary of 0.025.","statisticalMethod":"1-sided Log Rank Test","statisticalComment":"Stratified by stratification factors: histology (squamous vs non-squamous) and line of therapy (second vs third).","paramType":"Hazard Ratio (HR)","paramValue":"0.53","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.407","ciUpperLimit":"0.702"}]},{"type":"SECONDARY","title":"Objective Response Rate (ORR) in All Participants","description":"Objective response rate is defined as the percentage of participants who had a complete response (CR) or partial response (PR) as assessed by the investigator per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 Tumor assessments included computed tomography (CT) scans or magnetic resonance imaging (MRI), with preference for CT, of the chest, abdomen, and pelvis.\n\nCR: Disappearance of all target and non-target lesions and no new lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \\< 10 mm.\n\nPR: At least a 30% decrease in the size of target lesions and no progression of non-target lesions and no new lesions, or disappearance of all target lesions with persistence of one or more non-target lesion(s) and/or maintenance of tumor marker level above the normal limits and no new lesions.","populationDescription":"Intent-to-Treat Analysis Set","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"percentage of participants","timeFrame":"From randomization up to the final efficacy analysis data cut-off date of 15 July 2021; Up to 43 months","groups":[{"id":"OG000","title":"Tislelizumab","description":"Participants received tislelizumab 200 mg IV once every 3 weeks until disease progression, unacceptable toxicity, or withdrawal of informed consent, whichever occurred first."},{"id":"OG001","title":"Docetaxel","description":"Participants received docetaxel 75 mg/m² IV once every 3 weeks until disease progression, unacceptable toxicity, or withdrawal of informed consent, whichever occurred first."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"535"},{"groupId":"OG001","value":"270"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"22.6","lowerLimit":"19.14","upperLimit":"26.40"},{"groupId":"OG001","value":"7.0","lowerLimit":"4.29","upperLimit":"10.77"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"<0.0001","statisticalMethod":"Cochran-Mantel-Haenszel","statisticalComment":"Cochran-Mantel-Haenszel (CMH) chi-square test stratified by histology, line of therapy, and PDL1 expression.","paramType":"Odds Ratio (OR)","paramValue":"3.86","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"2.336","ciUpperLimit":"6.393"}]},{"type":"SECONDARY","title":"Objective Response Rate in PD-L1-Positive Participants","description":"Objective response rate is defined as the percentage of participants who had a complete response (CR) or partial response (PR) as assessed by the investigator per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 Tumor assessments included computed tomography (CT) scans or magnetic resonance imaging (MRI), with preference for CT, of the chest, abdomen, and pelvis.\n\nCR: Disappearance of all target and non-target lesions and no new lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \\< 10 mm.\n\nPR: At least a 30% decrease in the size of target lesions and no progression of non-target lesions and no new lesions, or disappearance of all target lesions with persistence of one or more non-target lesion(s) and/or maintenance of tumor marker level above the normal limits and no new lesions.","populationDescription":"The PD-L1-Positive Analysis Set included all randomized patients whose tumors were PD-L1 positive (defined as ≥ 25% of tumor cells with PD-L1 membrane staining).","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"percentage of participants","timeFrame":"From randomization up to the final efficacy analysis data cut-off date of 15 July 2021; Up to 43 months","groups":[{"id":"OG000","title":"Tislelizumab","description":"Participants received tislelizumab 200 mg IV once every 3 weeks until disease progression, unacceptable toxicity, or withdrawal of informed consent, whichever occurred first."},{"id":"OG001","title":"Docetaxel","description":"Participants received docetaxel 75 mg/m² IV once every 3 weeks until disease progression, unacceptable toxicity, or withdrawal of informed consent, whichever occurred first."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"227"},{"groupId":"OG001","value":"115"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"37.4","lowerLimit":"31.13","upperLimit":"44.09"},{"groupId":"OG001","value":"7.0","lowerLimit":"3.05","upperLimit":"13.25"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"<0.0001","statisticalMethod":"Cochran-Mantel-Haenszel","statisticalComment":"Cochran-Mantel-Haenszel (CMH) chi-square test stratified by histology and line of therapy.","paramType":"Odds Ratio (OR)","paramValue":"8.04","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"3.721","ciUpperLimit":"17.379"}]},{"type":"SECONDARY","title":"Duration of Response (DOR) for All Responders","description":"DoR was defined as the time from the first documented objective response to documented disease progression as assessed by the investigator using RECIST v1.1, or death from any cause, whichever occurred first.\n\nMedian DOR was estimated using the Kaplan-Meier method.\n\nProgressive Disease (PD): At least a 20% increase in the size of target lesions with an absolute increase of at least 5 mm, or unequivocal progression of existing non-target lesions, or the appearance of any new lesions.","populationDescription":"Participants in the Intent-to-Treat Analysis Set who had an objective response","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"months","timeFrame":"From randomization up to the final efficacy analysis data cut-off date of 15 July 2021; Up to 43 months","groups":[{"id":"OG000","title":"Tislelizumab","description":"Participants received tislelizumab 200 mg IV once every 3 weeks until disease progression, unacceptable toxicity, or withdrawal of informed consent, whichever occurred first."},{"id":"OG001","title":"Docetaxel","description":"Participants received docetaxel 75 mg/m² IV once every 3 weeks until disease progression, unacceptable toxicity, or withdrawal of informed consent, whichever occurred first."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"121"},{"groupId":"OG001","value":"19"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"13.5","lowerLimit":"8.54","upperLimit":"19.58"},{"groupId":"OG001","value":"6.0","lowerLimit":"2.10","upperLimit":"7.16"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"<0.0001","statisticalMethod":"Log Rank","statisticalComment":"Stratified by stratification factors: histology (squamous vs non-squamous), line of therapy (second vs third), and PDL1 expression (≥25% vs \\<25% TC).","paramType":"Hazard Ratio (HR)","paramValue":"0.31","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.176","ciUpperLimit":"0.536","estimateComment":"A stratified Cox proportional hazards model with Efron's method of tie handling was used to determine hazard ratio (HR) and its 95% CI."}]},{"type":"SECONDARY","title":"Duration of Response (DOR) in PD-L1-Positive Responders","description":"DoR was defined as the time from the first documented objective response to documented disease progression as assessed by the investigator using RECIST v1.1, or death from any cause, whichever occurred first.\n\nMedian DOR was estimated using the Kaplan-Meier method.\n\nProgressive Disease (PD): At least a 20% increase in the size of target lesions with an absolute increase of at least 5 mm, or unequivocal progression of existing non-target lesions, or the appearance of any new lesions.","populationDescription":"Participants in the PD-L1-Positive Analysis Set who had an objective response","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"months","timeFrame":"From randomization up to the final efficacy analysis data cut-off date of 15 July 2021; Up to 43 months","groups":[{"id":"OG000","title":"Tislelizumab","description":"Participants received tislelizumab 200 mg IV once every 3 weeks until disease progression, unacceptable toxicity, or withdrawal of informed consent, whichever occurred first."},{"id":"OG001","title":"Docetaxel","description":"Participants received docetaxel 75 mg/m² IV once every 3 weeks until disease progression, unacceptable toxicity, or withdrawal of informed consent, whichever occurred first."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"85"},{"groupId":"OG001","value":"8"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"11.9","lowerLimit":"8.31","upperLimit":"19.58"},{"groupId":"OG001","value":"4.2","lowerLimit":"0.56","upperLimit":"6.05"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"<0.0001","statisticalMethod":"Log Rank","statisticalComment":"Stratified by stratification factors: histology (squamous vs non-squamous) and line of therapy (second vs third).","paramType":"Hazard Ratio (HR)","paramValue":"0.16","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.066","ciUpperLimit":"0.370","estimateComment":"A stratified Cox proportional hazards model with Efron's method of tie handling was used to determine hazard ratio (HR) and its 95% CI."}]},{"type":"SECONDARY","title":"Progression-free Survival (PFS) in All Participants","description":"PFS was defined as the time from randomization to the first objectively documented disease progression as assessed by the investigator per RECIST v1.1 or death from any cause, whichever occurred first.\n\nMedian PFS was estimated using the Kaplan-Meier method.","populationDescription":"Intent-to-Treat Analysis Set","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"months","timeFrame":"From randomization up to the final efficacy analysis data cut-off date of 15 July 2021; Up to 43 months","groups":[{"id":"OG000","title":"Tislelizumab","description":"Participants received tislelizumab 200 mg IV once every 3 weeks until disease progression, unacceptable toxicity, or withdrawal of informed consent, whichever occurred first."},{"id":"OG001","title":"Docetaxel","description":"Participants received docetaxel 75 mg/m² IV once every 3 weeks until disease progression, unacceptable toxicity, or withdrawal of informed consent, whichever occurred first."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"535"},{"groupId":"OG001","value":"270"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.2","lowerLimit":"3.88","upperLimit":"5.52"},{"groupId":"OG001","value":"2.6","lowerLimit":"2.17","upperLimit":"3.78"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"<0.0001","statisticalMethod":"Log Rank","statisticalComment":"Stratified by stratification factors: histology (squamous vs non-squamous), line of therapy (second vs third), and PDL1 expression (≥25% vs \\<25% TC).","paramType":"Hazard Ratio (HR)","paramValue":"0.63","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.528","ciUpperLimit":"0.745","estimateComment":"A stratified Cox proportional hazards model with Efron's method of tie handling was used to determine hazard ratio (HR) and its 95% CI."}]},{"type":"SECONDARY","title":"Progression-free Survival in PD-L1 Positive Participants","description":"PFS was defined as the time from randomization to the first objectively documented disease progression as assessed by the investigator per RECIST v1.1 or death from any cause, whichever occurred first.\n\nMedian PFS was estimated using the Kaplan-Meier method.","populationDescription":"PD-L1 Positive Analysis Set","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"months","timeFrame":"From randomization up to the final efficacy analysis data cut-off date of 15 July 2021; Up to 43 months","groups":[{"id":"OG000","title":"Tislelizumab","description":"Participants received tislelizumab 200 mg IV once every 3 weeks until disease progression, unacceptable toxicity, or withdrawal of informed consent, whichever occurred first."},{"id":"OG001","title":"Docetaxel","description":"Participants received docetaxel 75 mg/m² IV once every 3 weeks until disease progression, unacceptable toxicity, or withdrawal of informed consent, whichever occurred first."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"227"},{"groupId":"OG001","value":"115"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.5","lowerLimit":"6.24","upperLimit":"8.28"},{"groupId":"OG001","value":"2.5","lowerLimit":"2.10","upperLimit":"4.11"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"<0.0001","statisticalMethod":"Log Rank","statisticalComment":"Stratified by stratification factors: histology (squamous vs non-squamous) and line of therapy (second vs third).","paramType":"Hazard Ratio (HR)","paramValue":"0.38","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.285","ciUpperLimit":"0.494","estimateComment":"A stratified Cox proportional hazards model with Efron's method of tie handling was used to determine hazard ratio (HR) and its 95% confidence interval (CI)."}]},{"type":"SECONDARY","title":"Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Global Health Status (GHS)/Quality of Life (QOL) Score","description":"The EORTC QLQ-30 contains 30 questions that incorporate 5 functional scales (physical functioning, role functioning, emotional functioning, cognitive functioning, and social functioning), 1 global health status scale, 3 symptom scales (fatigue, nausea and vomiting, and pain), and 6 single items (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties). The participant answers questions about their health during the past week. There are 28 questions answered on a 4-point scale where 1 = Not at all (best) and 4 = Very Much (worst) and two global health quality of life (QOL) questions answered on a 7-point scale where 1 = Very poor and 7 = Excellent. Raw scores are transformed into a 0 to 100 scale via linear transformation. Higher scores in GHS/QoL score indicates better quality of life.","populationDescription":"The HRQoL Analysis Set included all randomized participants who received ≥ 1 dose of study drug and completed ≥ 1 HRQoL assessment; participants with available data at baseline and Cycle 6 are included in the analysis.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"score on a scale","timeFrame":"Baseline and Cycle 6 (each cycle was 3 weeks)","groups":[{"id":"OG000","title":"Tislelizumab","description":"Participants received tislelizumab 200 mg IV once every 3 weeks until disease progression, unacceptable toxicity, or withdrawal of informed consent, whichever occurred first."},{"id":"OG001","title":"Docetaxel","description":"Participants received docetaxel 75 mg/m² IV once every 3 weeks until disease progression, unacceptable toxicity, or withdrawal of informed consent, whichever occurred first."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"316"},{"groupId":"OG001","value":"76"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.4","lowerLimit":"0.62","upperLimit":"4.12"},{"groupId":"OG001","value":"-3.4","lowerLimit":"-6.45","upperLimit":"-0.27"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"The linear mixed-effect model for repeated measures (MMRM) includes baseline score, stratification factors, treatment arm, visit, and treatment arm by visit interaction as fixed effects and visit as a repeated measure.","nonInferiorityType":"OTHER","pValue":"0.0008","statisticalMethod":"Mixed Models Analysis","paramType":"Least Squares (LS) Mean Difference","paramValue":"5.7","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"2.38","ciUpperLimit":"9.07"}]},{"type":"SECONDARY","title":"Change From Baseline in EORTC Quality of Life Questionnaire Lung Cancer 13 Items (QLQ-LC13) Coughing, Dyspnoea, and Chest Pain Scores","description":"The EORTC QLQ-LC13 is the lung cancer module of the QLQ-C30 and measures lung cancer-specific disease and treatment symptoms. It includes 13 questions about specific symptoms in which participants respond based on a 4-point scale, where 1 is \"not at all\" and 4 is \"very much\". Raw scores are transformed into a 0 to 100 scale via linear transformation. Lower scores indicate an improvement in symptoms.","populationDescription":"The HRQoL Analysis Set included all randomized participants who received ≥ 1 dose of study drug and completed ≥ 1 HRQoL assessment; participants with available data at baseline and Cycle 6 are included in the analysis.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"score on a scale","timeFrame":"Baseline and Cycle 6 (each cycle was 3 weeks)","groups":[{"id":"OG000","title":"Tislelizumab","description":"Participants received tislelizumab 200 mg IV once every 3 weeks until disease progression, unacceptable toxicity, or withdrawal of informed consent, whichever occurred first."},{"id":"OG001","title":"Docetaxel","description":"Participants received docetaxel 75 mg/m² IV once every 3 weeks until disease progression, unacceptable toxicity, or withdrawal of informed consent, whichever occurred first."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"316"},{"groupId":"OG001","value":"77"}]}],"classes":[{"title":"Coughing Scale","categories":[{"measurements":[{"groupId":"OG000","value":"-7.8","lowerLimit":"-10.23","upperLimit":"-5.30"},{"groupId":"OG001","value":"0.5","lowerLimit":"-3.87","upperLimit":"4.87"}]}]},{"title":"Dyspnoea Scale","categories":[{"measurements":[{"groupId":"OG000","value":"-1.2","lowerLimit":"-2.93","upperLimit":"0.56"},{"groupId":"OG001","value":"2.0","lowerLimit":"-1.01","upperLimit":"5.05"}]}]},{"title":"Chest Pain Scale","categories":[{"measurements":[{"groupId":"OG000","value":"-0.9","lowerLimit":"-2.86","upperLimit":"1.06"},{"groupId":"OG001","value":"1.3","lowerLimit":"-2.15","upperLimit":"4.84"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"Analysis of Change from Baseline in Coughing Scale. The linear mixed-effect model for repeated measures (MMRM) includes baseline score, stratification factors, treatment arm, visit, and treatment arm by visit interaction as fixed effects and visit as a repeated measure.","nonInferiorityType":"OTHER","pValue":"0.0007","statisticalMethod":"Mixed Models Analysis","paramType":"LS Mean Difference","paramValue":"-8.3","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-13.02","ciUpperLimit":"-3.51"},{"groupIds":["OG000","OG001"],"groupDescription":"Analysis of Change from Baseline in Dyspnoea Scale. The linear mixed-effect model for repeated measures (MMRM) includes baseline score, stratification factors, treatment arm, visit, and treatment arm by visit interaction as fixed effects and visit as a repeated measure.","nonInferiorityType":"OTHER","pValue":"0.0579","statisticalMethod":"Mixed Models Analysis","paramType":"LS Mean Difference","paramValue":"-3.2","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-6.52","ciUpperLimit":"0.11"},{"groupIds":["OG000","OG001"],"groupDescription":"Analysis of Change from Baseline in Chest Pain Scale. The linear mixed-effect model for repeated measures (MMRM) includes baseline score, stratification factors, treatment arm, visit, and treatment arm by visit interaction as fixed effects and visit as a repeated measure.","nonInferiorityType":"OTHER","pValue":"0.2472","statisticalMethod":"Mixed Models Analysis","paramType":"LS Mean Difference","paramValue":"-2.2","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-6.05","ciUpperLimit":"1.56"}]},{"type":"SECONDARY","title":"Change From Baseline in European Quality of Life 5-Dimensions, 5-level (EQ-5D-5L) Visual Analogue Scale (VAS)","description":"The EQ-5D-5L measures health outcomes using a VAS to record a participant's self-rated health on a scale from 0 to 100, where 100 is 'the best health you can imagine' and 0 is 'the worst health you can imagine.' A higher score indicates better health outcomes.","populationDescription":"The HRQoL Analysis Set included all randomized participants who received ≥ 1 dose of study drug and completed ≥ 1 HRQoL assessment; participants with available data at Baseline and Cycle 6 are included in the analysis.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"score on a scale","timeFrame":"Baseline and Cycle 6 (each cycle was 3 weeks)","groups":[{"id":"OG000","title":"Tislelizumab","description":"Participants received tislelizumab 200 mg IV once every 3 weeks until disease progression, unacceptable toxicity, or withdrawal of informed consent, whichever occurred first."},{"id":"OG001","title":"Docetaxel","description":"Participants received docetaxel 75 mg/m² IV once every 3 weeks until disease progression, unacceptable toxicity, or withdrawal of informed consent, whichever occurred first."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"237"},{"groupId":"OG001","value":"60"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.0","spread":"11.89"},{"groupId":"OG001","value":"1.7","spread":"11.36"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Treatment-emergent Adverse Events (TEAEs)","description":"An adverse event is defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study drug, whether considered related to study drug or not.\n\nThe investigator assessed the severity of each AE and graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) v4.03 as defined below:\n\n* Grade 1: Mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated.\n* Grade 2: Moderate; minimal, local or noninvasive intervention indicated; limiting age-appropriate activities of daily living.\n* Grade 3: Severe or medically significant but not immediately life threatening. hospitalization or prolongation of hospitalization indicated; disabling; limiting selfcare activities of daily living.\n* Grade 4: Life threatening consequences; urgent intervention indicated.\n* Grade 5: Death related to AE.","populationDescription":"The Safety Analysis Set included all randomized patients who received ≥ 1 dose of study drug.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"From first dose of study drug to 30 days after last dose, up to the study completion date cut-off date of 18 January 2024 (up to approximately 63 months)","groups":[{"id":"OG000","title":"Tislelizumab","description":"Participants received tislelizumab 200 mg IV once every 3 weeks until disease progression, unacceptable toxicity, or withdrawal of informed consent, whichever occurred first."},{"id":"OG001","title":"Docetaxel","description":"Participants received docetaxel 75 mg/m² IV once every 3 weeks until disease progression, unacceptable toxicity, or withdrawal of informed consent, whichever occurred first."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"534"},{"groupId":"OG001","value":"258"}]}],"classes":[{"title":"Any TEAE","categories":[{"measurements":[{"groupId":"OG000","value":"518"},{"groupId":"OG001","value":"254"}]}]},{"title":"≥ Grade 3 TEAE","categories":[{"measurements":[{"groupId":"OG000","value":"233"},{"groupId":"OG001","value":"193"}]}]}]}]},"adverseEventsModule":{"frequencyThreshold":"3","timeFrame":"All-cause mortality is reported from randomization up to study completion date cut-off date of 18 January 2024, up to 63 months. AEs are reported from first dose of study drug to 30 days after last dose, up to study completion date cut-off date of 18 January 2024, up to 63 months.","description":"All-cause mortality is reported for all randomized participants. Serious and other adverse events includes all randomized participants who received ≥ 1 dose of any study treatment.","eventGroups":[{"id":"EG000","title":"Tislelizumab","description":"Participants received tislelizumab 200 mg IV once every 3 weeks until disease progression, unacceptable toxicity, or withdrawal of informed consent, whichever occurred first.","deathsNumAffected":409,"deathsNumAtRisk":535,"seriousNumAffected":192,"seriousNumAtRisk":534,"otherNumAffected":498,"otherNumAtRisk":534},{"id":"EG001","title":"Docetaxel","description":"Participants received docetaxel 75 mg/m² IV once every 3 weeks until disease progression, unacceptable toxicity, or withdrawal of informed consent, whichever occurred first.","deathsNumAffected":223,"deathsNumAtRisk":270,"seriousNumAffected":84,"seriousNumAtRisk":258,"otherNumAffected":246,"otherNumAtRisk":258}],"seriousEvents":[{"term":"Agranulocytosis","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":534},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":258}]},{"term":"Anaemia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":534},{"groupId":"EG001","numEvents":5,"numAffected":5,"numAtRisk":258}]},{"term":"Disseminated intravascular coagulation","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":534},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":258}]},{"term":"Febrile neutropenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":534},{"groupId":"EG001","numEvents":22,"numAffected":21,"numAtRisk":258}]},{"term":"Leukopenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":534},{"groupId":"EG001","numEvents":7,"numAffected":6,"numAtRisk":258}]},{"term":"Lymphadenitis","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":534},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":258}]},{"term":"Neutropenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":534},{"groupId":"EG001","numEvents":12,"numAffected":11,"numAtRisk":258}]},{"term":"Thrombocytopenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":534},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":258}]},{"term":"Acute coronary syndrome","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":534},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":258}]},{"term":"Acute left ventricular failure","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":534},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":258}]},{"term":"Acute myocardial infarction","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":534},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":258}]},{"term":"Atrial fibrillation","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":534},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":258}]},{"term":"Atrioventricular block","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":534},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":258}]},{"term":"Cardiac tamponade","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":534},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":258}]},{"term":"Cardiogenic shock","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":534},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":258}]},{"term":"Coronary artery disease","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":534},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":258}]},{"term":"Myocardial infarction","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":534},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":258}]},{"term":"Myocardial ischaemia","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":534},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":258}]},{"term":"Myocarditis","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":534},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":258}]},{"term":"Pericardial effusion","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":5,"numAtRisk":534},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":258}]},{"term":"Adrenal insufficiency","organSystem":"Endocrine disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":534},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":258}]},{"term":"Glucocorticoid deficiency","organSystem":"Endocrine disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":534},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":258}]},{"term":"Immune-mediated adrenal insuficiency","organSystem":"Endocrine disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":534},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":258}]},{"term":"Retinal tear","organSystem":"Eye disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":534},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":258}]},{"term":"Abdominal pain","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":534},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":258}]},{"term":"Abdominal pain upper","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":534},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":258}]},{"term":"Diarrhoea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":534},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":258}]},{"term":"Duodenal ulcer","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":534},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":258}]},{"term":"Dyspepsia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":534},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":258}]},{"term":"Dysphagia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":534},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":258}]},{"term":"Enteritis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":534},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":258}]},{"term":"Immune-mediated enterocolitis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":534},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":258}]},{"term":"Intestinal obstruction","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":534},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":258}]},{"term":"Nausea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":534},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":258}]},{"term":"Pancreatitis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":534},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":258}]},{"term":"Pancreatitis acute","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":534},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":258}]},{"term":"Small intestinal obstruction","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":534},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":258}]},{"term":"Upper gastrointestinal haemorrhage","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":1,"numAtRisk":534},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":258}]},{"term":"Vomiting","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":534},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":258}]},{"term":"Asthenia","organSystem":"General disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":534},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":258}]},{"term":"Chest discomfort","organSystem":"General disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":534},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":258}]},{"term":"Chest pain","organSystem":"General disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":534},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":258}]},{"term":"Chills","organSystem":"General disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":534},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":258}]},{"term":"Death","organSystem":"General disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":6,"numAtRisk":534},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":258}]},{"term":"Fatigue","organSystem":"General disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":534},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":258}]},{"term":"General physical health deterioration","organSystem":"General disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":534},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":258}]},{"term":"Malaise","organSystem":"General disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":534},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":258}]},{"term":"Multiple organ dysfunction syndrome","organSystem":"General disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":534},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":258}]},{"term":"Non-cardiac chest pain","organSystem":"General disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":534},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":258}]},{"term":"Pyrexia","organSystem":"General disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":534},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":258}]},{"term":"Acute hepatic failure","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":534},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":258}]},{"term":"Autoimmune hepatitis","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":534},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":258}]},{"term":"Cholecystitis","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":534},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":258}]},{"term":"Cholecystitis acute","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":534},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":258}]},{"term":"Drug-induced liver injury","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":534},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":258}]},{"term":"Hepatic function abnormal","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":534},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":258}]},{"term":"Hepatitis","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":534},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":258}]},{"term":"Jaundice cholestatic","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":534},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":258}]},{"term":"Drug hypersensitivity","organSystem":"Immune system disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":534},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":258}]},{"term":"Bronchitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":534},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":258}]},{"term":"COVID-19","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":534},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":258}]},{"term":"Lower respiratory tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":534},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":258}]},{"term":"Otitis media chronic","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":534},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":258}]},{"term":"Pneumonia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":48,"numAffected":39,"numAtRisk":534},{"groupId":"EG001","numEvents":21,"numAffected":19,"numAtRisk":258}]},{"term":"Pneumonia bacterial","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":534},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":258}]},{"term":"Pneumonia haemophilus","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":534},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":258}]},{"term":"Septic shock","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":534},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":258}]},{"term":"Upper respiratory tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":534},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":258}]},{"term":"Cerebral radiation injury","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":534},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":258}]},{"term":"Clavicle fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":534},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":258}]},{"term":"Femur fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":534},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":258}]},{"term":"Forearm fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":534},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":258}]},{"term":"Ligament rupture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":534},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":258}]},{"term":"Limb injury","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":534},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":258}]},{"term":"Road traffic accident","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":534},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":258}]},{"term":"Spinal compression fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":534},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":258}]},{"term":"Spinal fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":534},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":258}]},{"term":"Upper limb fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":534},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":258}]},{"term":"Alanine aminotransferase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":534},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":258}]},{"term":"Aspartate aminotransferase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":534},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":258}]},{"term":"Blood creatine phosphokinase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":534},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":258}]},{"term":"Neutrophil count decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":534},{"groupId":"EG001","numEvents":10,"numAffected":8,"numAtRisk":258}]},{"term":"Platelet count decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":534},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":258}]},{"term":"White blood cell count decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":534},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":258}]},{"term":"Decreased appetite","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":5,"numAtRisk":534},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":258}]},{"term":"Electrolyte imbalance","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":534},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":258}]},{"term":"Hyperglycaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":534},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":258}]},{"term":"Hypokalaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":534},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":258}]},{"term":"Hyponatraemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":534},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":258}]},{"term":"Hypoproteinaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":534},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":258}]},{"term":"Ketoacidosis","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":534},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":258}]},{"term":"Type 1 diabetes mellitus","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":534},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":258}]},{"term":"Arthralgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":1,"numAtRisk":534},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":258}]},{"term":"Arthritis","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":534},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":258}]},{"term":"Back pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":534},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":258}]},{"term":"Bone pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":534},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":258}]},{"term":"Intervertebral disc protrusion","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":534},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":258}]},{"term":"Joint effusion","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":534},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":258}]},{"term":"Muscular weakness","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":534},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":258}]},{"term":"Myositis","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":534},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":258}]},{"term":"Pain in extremity","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":534},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":258}]},{"term":"Pathological fracture","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":534},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":258}]},{"term":"Spinal pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":534},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":258}]},{"term":"Cancer pain","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":534},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":258}]},{"term":"Colon adenoma","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":534},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":258}]},{"term":"Peritumoural oedema","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":534},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":258}]},{"term":"Tumour associated fever","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":534},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":258}]},{"term":"Tumour pain","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":534},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":258}]},{"term":"Brain oedema","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":534},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":258}]},{"term":"Cerebral artery occlusion","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":534},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":258}]},{"term":"Cerebral infarction","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":3,"numAtRisk":534},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":258}]},{"term":"Epilepsy","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":534},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":258}]},{"term":"Haemorrhage intracranial","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":534},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":258}]},{"term":"Headache","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":534},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":258}]},{"term":"Hemiparesis","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":534},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":258}]},{"term":"Intracranial pressure increased","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":534},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":258}]},{"term":"Seizure","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":1,"numAtRisk":534},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":258}]},{"term":"Spinal cord compression","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":2,"numAtRisk":534},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":258}]},{"term":"Syncope","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":534},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":258}]},{"term":"Transient ischaemic attack","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":534},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":258}]},{"term":"Visual pathway disorder","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":534},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":258}]},{"term":"Depression","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":534},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":258}]},{"term":"Suicide attempt","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":534},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":258}]},{"term":"Acute kidney injury","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":534},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":258}]},{"term":"Chronic kidney disease","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":534},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":258}]},{"term":"Haematuria","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":534},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":258}]},{"term":"Renal failure","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":534},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":258}]},{"term":"Urinary retention","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":534},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":258}]},{"term":"Acute respiratory failure","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":534},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":258}]},{"term":"Asthma","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":534},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":258}]},{"term":"Chronic obstructive pulmonary disease","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":534},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":258}]},{"term":"Cough","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":534},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":258}]},{"term":"Dyspnoea","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":8,"numAffected":8,"numAtRisk":534},{"groupId":"EG001","numEvents":5,"numAffected":5,"numAtRisk":258}]},{"term":"Haemoptysis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":11,"numAffected":10,"numAtRisk":534},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":258}]},{"term":"Hypoxia","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":534},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":258}]},{"term":"Immune-mediated lung disease","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":8,"numAffected":8,"numAtRisk":534},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":258}]},{"term":"Interstitial lung disease","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":7,"numAffected":7,"numAtRisk":534},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":258}]},{"term":"Pleural effusion","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":9,"numAffected":9,"numAtRisk":534},{"groupId":"EG001","numEvents":6,"numAffected":5,"numAtRisk":258}]},{"term":"Pneumonitis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":15,"numAffected":15,"numAtRisk":534},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":258}]},{"term":"Pneumothorax","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":534},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":258}]},{"term":"Pneumothorax spontaneous","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":534},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":258}]},{"term":"Pulmonary embolism","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":534},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":258}]},{"term":"Pulmonary haemorrhage","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":534},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":258}]},{"term":"Pulmonary oedema","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":534},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":258}]},{"term":"Pulmonary thrombosis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":534},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":258}]},{"term":"Respiratory failure","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":6,"numAtRisk":534},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":258}]},{"term":"Tracheal stenosis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":534},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":258}]},{"term":"Wheezing","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":534},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":258}]},{"term":"Embolism venous","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":534},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":258}]},{"term":"Hypertension","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":534},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":258}]},{"term":"Hypovolaemic shock","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":534},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":258}]},{"term":"Superior vena cava syndrome","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":534},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":258}]}],"otherEvents":[{"term":"Anaemia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":269,"numAffected":156,"numAtRisk":534},{"groupId":"EG001","numEvents":169,"numAffected":114,"numAtRisk":258}]},{"term":"Febrile neutropenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":534},{"groupId":"EG001","numEvents":13,"numAffected":13,"numAtRisk":258}]},{"term":"Leukopenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":38,"numAffected":17,"numAtRisk":534},{"groupId":"EG001","numEvents":169,"numAffected":70,"numAtRisk":258}]},{"term":"Neutropenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":24,"numAffected":10,"numAtRisk":534},{"groupId":"EG001","numEvents":185,"numAffected":73,"numAtRisk":258}]},{"term":"Thrombocytopenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":28,"numAffected":20,"numAtRisk":534},{"groupId":"EG001","numEvents":22,"numAffected":9,"numAtRisk":258}]},{"term":"Hyperthyroidism","organSystem":"Endocrine disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":23,"numAffected":23,"numAtRisk":534},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":258}]},{"term":"Hypothyroidism","organSystem":"Endocrine disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":82,"numAffected":66,"numAtRisk":534},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":258}]},{"term":"Cataract","organSystem":"Eye disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":23,"numAffected":22,"numAtRisk":534},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":258}]},{"term":"Abdominal distension","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":8,"numAffected":8,"numAtRisk":534},{"groupId":"EG001","numEvents":14,"numAffected":12,"numAtRisk":258}]},{"term":"Abdominal pain upper","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":20,"numAffected":16,"numAtRisk":534},{"groupId":"EG001","numEvents":11,"numAffected":10,"numAtRisk":258}]},{"term":"Constipation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":89,"numAffected":74,"numAtRisk":534},{"groupId":"EG001","numEvents":51,"numAffected":44,"numAtRisk":258}]},{"term":"Diarrhoea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":52,"numAffected":41,"numAtRisk":534},{"groupId":"EG001","numEvents":51,"numAffected":35,"numAtRisk":258}]},{"term":"Nausea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":73,"numAffected":65,"numAtRisk":534},{"groupId":"EG001","numEvents":55,"numAffected":43,"numAtRisk":258}]},{"term":"Stomatitis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":6,"numAtRisk":534},{"groupId":"EG001","numEvents":14,"numAffected":12,"numAtRisk":258}]},{"term":"Toothache","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":23,"numAffected":20,"numAtRisk":534},{"groupId":"EG001","numEvents":7,"numAffected":6,"numAtRisk":258}]},{"term":"Vomiting","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":44,"numAffected":35,"numAtRisk":534},{"groupId":"EG001","numEvents":23,"numAffected":19,"numAtRisk":258}]},{"term":"Asthenia","organSystem":"General disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":78,"numAffected":76,"numAtRisk":534},{"groupId":"EG001","numEvents":64,"numAffected":57,"numAtRisk":258}]},{"term":"Chest discomfort","organSystem":"General disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":19,"numAffected":19,"numAtRisk":534},{"groupId":"EG001","numEvents":8,"numAffected":8,"numAtRisk":258}]},{"term":"Chest pain","organSystem":"General disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":21,"numAffected":21,"numAtRisk":534},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":258}]},{"term":"Fatigue","organSystem":"General disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":40,"numAffected":37,"numAtRisk":534},{"groupId":"EG001","numEvents":31,"numAffected":24,"numAtRisk":258}]},{"term":"Malaise","organSystem":"General disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":44,"numAffected":40,"numAtRisk":534},{"groupId":"EG001","numEvents":28,"numAffected":17,"numAtRisk":258}]},{"term":"Non-cardiac chest pain","organSystem":"General disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":29,"numAffected":22,"numAtRisk":534},{"groupId":"EG001","numEvents":9,"numAffected":7,"numAtRisk":258}]},{"term":"Oedema peripheral","organSystem":"General disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":15,"numAffected":15,"numAtRisk":534},{"groupId":"EG001","numEvents":11,"numAffected":10,"numAtRisk":258}]},{"term":"Pyrexia","organSystem":"General disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":72,"numAffected":62,"numAtRisk":534},{"groupId":"EG001","numEvents":29,"numAffected":26,"numAtRisk":258}]},{"term":"Pneumonia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":43,"numAffected":40,"numAtRisk":534},{"groupId":"EG001","numEvents":19,"numAffected":18,"numAtRisk":258}]},{"term":"Upper respiratory tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":76,"numAffected":55,"numAtRisk":534},{"groupId":"EG001","numEvents":25,"numAffected":23,"numAtRisk":258}]},{"term":"Alanine aminotransferase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":183,"numAffected":112,"numAtRisk":534},{"groupId":"EG001","numEvents":47,"numAffected":39,"numAtRisk":258}]},{"term":"Aspartate aminotransferase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":172,"numAffected":106,"numAtRisk":534},{"groupId":"EG001","numEvents":38,"numAffected":32,"numAtRisk":258}]},{"term":"Bilirubin conjugated increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":25,"numAffected":17,"numAtRisk":534},{"groupId":"EG001","numEvents":9,"numAffected":7,"numAtRisk":258}]},{"term":"Blood alkaline phosphatase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":53,"numAffected":39,"numAtRisk":534},{"groupId":"EG001","numEvents":13,"numAffected":10,"numAtRisk":258}]},{"term":"Blood bilirubin increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":49,"numAffected":36,"numAtRisk":534},{"groupId":"EG001","numEvents":23,"numAffected":15,"numAtRisk":258}]},{"term":"Blood creatine phosphokinase MB increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":34,"numAffected":21,"numAtRisk":534},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":258}]},{"term":"Blood creatine phosphokinase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":97,"numAffected":47,"numAtRisk":534},{"groupId":"EG001","numEvents":4,"numAffected":2,"numAtRisk":258}]},{"term":"Blood creatinine increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":58,"numAffected":37,"numAtRisk":534},{"groupId":"EG001","numEvents":22,"numAffected":17,"numAtRisk":258}]},{"term":"Blood lactate dehydrogenase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":48,"numAffected":38,"numAtRisk":534},{"groupId":"EG001","numEvents":23,"numAffected":18,"numAtRisk":258}]},{"term":"Blood thyroid stimulating hormone increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":56,"numAffected":32,"numAtRisk":534},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":258}]},{"term":"Blood urea increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":38,"numAffected":26,"numAtRisk":534},{"groupId":"EG001","numEvents":7,"numAffected":7,"numAtRisk":258}]},{"term":"Gamma-glutamyltransferase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":47,"numAffected":31,"numAtRisk":534},{"groupId":"EG001","numEvents":19,"numAffected":15,"numAtRisk":258}]},{"term":"Lymphocyte count decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":76,"numAffected":35,"numAtRisk":534},{"groupId":"EG001","numEvents":37,"numAffected":18,"numAtRisk":258}]},{"term":"Neutrophil count decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":38,"numAffected":17,"numAtRisk":534},{"groupId":"EG001","numEvents":168,"numAffected":90,"numAtRisk":258}]},{"term":"Neutrophil count increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":23,"numAffected":19,"numAtRisk":534},{"groupId":"EG001","numEvents":9,"numAffected":7,"numAtRisk":258}]},{"term":"Platelet count decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":37,"numAffected":21,"numAtRisk":534},{"groupId":"EG001","numEvents":11,"numAffected":9,"numAtRisk":258}]},{"term":"Weight decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":101,"numAffected":90,"numAtRisk":534},{"groupId":"EG001","numEvents":32,"numAffected":31,"numAtRisk":258}]},{"term":"White blood cell count decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":58,"numAffected":21,"numAtRisk":534},{"groupId":"EG001","numEvents":133,"numAffected":75,"numAtRisk":258}]},{"term":"White blood cell count increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":30,"numAffected":20,"numAtRisk":534},{"groupId":"EG001","numEvents":13,"numAffected":11,"numAtRisk":258}]},{"term":"Decreased appetite","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":95,"numAffected":88,"numAtRisk":534},{"groupId":"EG001","numEvents":71,"numAffected":62,"numAtRisk":258}]},{"term":"Hyperglycaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":111,"numAffected":56,"numAtRisk":534},{"groupId":"EG001","numEvents":37,"numAffected":29,"numAtRisk":258}]},{"term":"Hyperuricaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":52,"numAffected":24,"numAtRisk":534},{"groupId":"EG001","numEvents":10,"numAffected":7,"numAtRisk":258}]},{"term":"Hypoalbuminaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":141,"numAffected":76,"numAtRisk":534},{"groupId":"EG001","numEvents":64,"numAffected":40,"numAtRisk":258}]},{"term":"Hypocalcaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":49,"numAffected":29,"numAtRisk":534},{"groupId":"EG001","numEvents":26,"numAffected":21,"numAtRisk":258}]},{"term":"Hypochloraemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":29,"numAffected":19,"numAtRisk":534},{"groupId":"EG001","numEvents":13,"numAffected":11,"numAtRisk":258}]},{"term":"Hypokalaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":83,"numAffected":51,"numAtRisk":534},{"groupId":"EG001","numEvents":16,"numAffected":14,"numAtRisk":258}]},{"term":"Hyponatraemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":85,"numAffected":53,"numAtRisk":534},{"groupId":"EG001","numEvents":37,"numAffected":28,"numAtRisk":258}]},{"term":"Hypophosphataemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":25,"numAffected":11,"numAtRisk":534},{"groupId":"EG001","numEvents":16,"numAffected":9,"numAtRisk":258}]},{"term":"Hypoproteinaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":27,"numAffected":22,"numAtRisk":534},{"groupId":"EG001","numEvents":8,"numAffected":7,"numAtRisk":258}]},{"term":"Arthralgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":83,"numAffected":68,"numAtRisk":534},{"groupId":"EG001","numEvents":30,"numAffected":23,"numAtRisk":258}]},{"term":"Back pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":47,"numAffected":41,"numAtRisk":534},{"groupId":"EG001","numEvents":21,"numAffected":20,"numAtRisk":258}]},{"term":"Myalgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":6,"numAtRisk":534},{"groupId":"EG001","numEvents":19,"numAffected":16,"numAtRisk":258}]},{"term":"Pain in extremity","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":36,"numAffected":29,"numAtRisk":534},{"groupId":"EG001","numEvents":23,"numAffected":17,"numAtRisk":258}]},{"term":"Cancer pain","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":25,"numAffected":21,"numAtRisk":534},{"groupId":"EG001","numEvents":9,"numAffected":8,"numAtRisk":258}]},{"term":"Dizziness","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":21,"numAffected":19,"numAtRisk":534},{"groupId":"EG001","numEvents":15,"numAffected":13,"numAtRisk":258}]},{"term":"Headache","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":28,"numAffected":23,"numAtRisk":534},{"groupId":"EG001","numEvents":12,"numAffected":12,"numAtRisk":258}]},{"term":"Hypoaesthesia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":6,"numAtRisk":534},{"groupId":"EG001","numEvents":13,"numAffected":13,"numAtRisk":258}]},{"term":"Peripheral sensory neuropathy","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":534},{"groupId":"EG001","numEvents":10,"numAffected":9,"numAtRisk":258}]},{"term":"Insomnia","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":58,"numAffected":34,"numAtRisk":534},{"groupId":"EG001","numEvents":29,"numAffected":26,"numAtRisk":258}]},{"term":"Proteinuria","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":26,"numAffected":17,"numAtRisk":534},{"groupId":"EG001","numEvents":6,"numAffected":6,"numAtRisk":258}]},{"term":"Cough","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":128,"numAffected":111,"numAtRisk":534},{"groupId":"EG001","numEvents":46,"numAffected":40,"numAtRisk":258}]},{"term":"Dyspnoea","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":64,"numAffected":62,"numAtRisk":534},{"groupId":"EG001","numEvents":35,"numAffected":31,"numAtRisk":258}]},{"term":"Haemoptysis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":62,"numAffected":51,"numAtRisk":534},{"groupId":"EG001","numEvents":18,"numAffected":17,"numAtRisk":258}]},{"term":"Productive cough","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":49,"numAffected":36,"numAtRisk":534},{"groupId":"EG001","numEvents":22,"numAffected":22,"numAtRisk":258}]},{"term":"Alopecia","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":7,"numAffected":7,"numAtRisk":534},{"groupId":"EG001","numEvents":130,"numAffected":127,"numAtRisk":258}]},{"term":"Pruritus","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":44,"numAffected":41,"numAtRisk":534},{"groupId":"EG001","numEvents":5,"numAffected":5,"numAtRisk":258}]},{"term":"Rash","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":41,"numAffected":38,"numAtRisk":534},{"groupId":"EG001","numEvents":7,"numAffected":7,"numAtRisk":258}]},{"term":"Hypertension","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":32,"numAffected":25,"numAtRisk":534},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":258}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":false,"restrictionType":"OTHER","restrictiveAgreement":true,"otherDetails":"BeiGene has 18 months from the end of the study at all sites to publish overall study results. After the 1st multi-site publication or the expiration of publication period, Investigators are free to publish/present the results of the study. Investigators must submit all draft publications/presentations to us for review 60 days prior to the planned publication/presentation date. BeiGene may request deletion of its confidential information \\& may request a further delay to protect its IP rights."},"pointOfContact":{"title":"Study Director","organization":"BeiGene","email":"Clinicaltrials@beigene.com","phone":"1-877-828-5568"}}},"documentSection":{"largeDocumentModule":{"largeDocs":[{"typeAbbrev":"Prot","hasProtocol":true,"hasSap":false,"hasIcf":false,"label":"Study Protocol","date":"2020-03-09","uploadDate":"2025-01-15T11:03","filename":"Prot_000.pdf","size":1652252},{"typeAbbrev":"SAP","hasProtocol":false,"hasSap":true,"hasIcf":false,"label":"Statistical Analysis Plan","date":"2020-10-16","uploadDate":"2025-01-15T11:06","filename":"SAP_001.pdf","size":788522}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2025-12-17"},"conditionBrowseModule":{"meshes":[{"id":"D002289","term":"Carcinoma, Non-Small-Cell Lung"}],"ancestors":[{"id":"D002283","term":"Carcinoma, Bronchogenic"},{"id":"D001984","term":"Bronchial Neoplasms"},{"id":"D008175","term":"Lung Neoplasms"},{"id":"D012142","term":"Respiratory Tract Neoplasms"},{"id":"D013899","term":"Thoracic Neoplasms"},{"id":"D009371","term":"Neoplasms by Site"},{"id":"D009369","term":"Neoplasms"},{"id":"D008171","term":"Lung Diseases"},{"id":"D012140","term":"Respiratory Tract Diseases"}]},"interventionBrowseModule":{"meshes":[{"id":"C000707970","term":"tislelizumab"},{"id":"D000077143","term":"Docetaxel"}],"ancestors":[{"id":"D043823","term":"Taxoids"},{"id":"D043822","term":"Cyclodecanes"},{"id":"D003516","term":"Cycloparaffins"},{"id":"D006840","term":"Hydrocarbons, Alicyclic"},{"id":"D006844","term":"Hydrocarbons, Cyclic"},{"id":"D006838","term":"Hydrocarbons"},{"id":"D009930","term":"Organic Chemicals"},{"id":"D004224","term":"Diterpenes"},{"id":"D013729","term":"Terpenes"}]}},"hasResults":true}